Genetic ‘Trojan horse’ selectively kills cancer cells linked to Kaposi’s sarcoma

LANA-1_immunostain_in_a_Kaposi_sarcoma_in_a_patient_with_HHV8-associated_MCD

Source: Amylacea

A highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus harnesses an adeno-associated virus (AAV) to deliver a genetic “Trojan horse” into infected cells.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE